Mentally ill prison inmates denied drugs, say prison medics
Interior Ministry cutbacks mean doctors must seek approval for treatment, despite 45-percent rate of illness among convicts
Prison doctors say that mentally ill prison inmates are being denied one of the most commonly used medications because of budget cuts to the penitentiary health system. Since March 26, physicians can no longer prescribe pregabalin without special permission. This drug is commonly used to treat anxiety disorders caused by conditions such as drug addiction.
Now, doctors are sending in their written requests to the secretary general of Penitentiary Institutions, but "90 percent of requests are being denied," according to the Spanish Society for Penitentiary Health.
Over 45 percent of the 75,000 inmates serving time in Spanish prisons suffer from some form of mental illness, according to a 2011 joint report by this group and the Spanish Association of Neuropsychiatry. This study states that the most common condition is caused by drug use (76.2 percent), followed by general anxiety disorder (45.3 percent). In both cases, treatment with pregabalin is often "the one that guarantees the best results by far," says Antonio López Burgos, president of the Spanish Society of Penitentiary Medicine.
The price of the treatment is around one euro a day per inmate, and until now doctors were prescribing it to hundreds of patients with epilepsy, neuropathic pain or general anxiety disorder. It is this last condition that the government is refusing to treat with pregabalin "in the vast majority of cases" ever since the Interior Ministry imposed the need for special permission.
A spokesman for Penitentiary Institutions said the same procedure is used for many drugs in most regions, and that it is part of a drive to cut annual medication costs in excess of 35 million euros. "The goal is for everyone who needs medication to get it, but for those who don't need it not to get it."
Tu suscripción se está usando en otro dispositivo
¿Quieres añadir otro usuario a tu suscripción?
Si continúas leyendo en este dispositivo, no se podrá leer en el otro.
FlechaTu suscripción se está usando en otro dispositivo y solo puedes acceder a EL PAÍS desde un dispositivo a la vez.
Si quieres compartir tu cuenta, cambia tu suscripción a la modalidad Premium, así podrás añadir otro usuario. Cada uno accederá con su propia cuenta de email, lo que os permitirá personalizar vuestra experiencia en EL PAÍS.
¿Tienes una suscripción de empresa? Accede aquí para contratar más cuentas.
En el caso de no saber quién está usando tu cuenta, te recomendamos cambiar tu contraseña aquí.
Si decides continuar compartiendo tu cuenta, este mensaje se mostrará en tu dispositivo y en el de la otra persona que está usando tu cuenta de forma indefinida, afectando a tu experiencia de lectura. Puedes consultar aquí los términos y condiciones de la suscripción digital.
Últimas noticias
The complicated life of Francesca Albanese: A rising figure in Italy but barred from every bank by Trump’s sanctions
Reinhard Genzel, Nobel laureate in physics: ‘One-minute videos will never give you the truth’
Pinochet’s victims grapple with José Antonio Kast’s rise in Chile
How Japan is trying to avert ‘digital defeat’
Most viewed
- Why we lost the habit of sleeping in two segments and how that changed our sense of time
- Pablo Escobar’s hippos: A serious environmental problem, 40 years on
- Trump’s obsession with putting his name on everything is unprecedented in the United States
- The Florida Keys tourist paradise is besieged by immigration agents: ‘We’ve never seen anything like this’
- Charles Dubouloz, mountaineering star, retires at 36 with a farewell tour inspired by Walter Bonatti









































